Selected article for: "enveloped virus and spike protein"
Author: Fluckiger, Anne-Catherine; Ontsouka, Barthelemy; Bozic, Jasminka; Diress, Abebaw; Ahmed, Tanvir; Berthoud, Tamara; Tran, Anh; Duque, Diane; Liao, Mingmin; McCluskie, Michael; Diaz-Mitoma, Francisco; Anderson, David E.; Soare, Catalina
Title: An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity
  • Cord-id: l8r04hdm
  • Document date: 2021_7_16
    • ID: l8r04hdm
    Snippet: We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs
    Document: We evaluated enveloped virus-like particles (eVLPs) expressing various forms of the Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein and several adjuvants in an effort to identify a highly potent Coronavirus disease 2019 (COVID-19) vaccine candidate. eVLPs expressing a modified prefusion form of SARS-CoV-2 spike protein were selected as they induced high antibody binding titers and neutralizing activity after a single injection in mice. Formulation of SARS-CoV-2 S eVLPs with aluminum phosphate resulted in balanced induction of IgG2 and IgG1 isotypes and antibody binding and neutralization titers were undiminished for more than 3 months after a single immunization. A single dose of this candidate, named VBI-2902a, protected Syrian golden hamsters from challenge with SARS-CoV-2 and supports the on-going clinical evaluation of VBI-2902a as a highly potent vaccine against COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activation release and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation release and adjuvant system: 1
    • acute respiratory syndrome and adjuvant potency: 1, 2
    • acute respiratory syndrome and adjuvant system: 1, 2
    • acute respiratory syndrome and load analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and localization expression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and log10 titer: 1